ANTARES PHARMA, INC. (NASDAQ:ATRS) Files An 8-K Submission of Matters to a Vote of Security Holders

ANTARES PHARMA, INC. (NASDAQ:ATRS) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07

Story continues below

Submission of Matters to a Vote of Security Holders.

The Annual Meeting of Stockholders of Antares Pharma, Inc. (the “Company”) was held on June 8, 2018. The following proposals, all of which were set forth in the Company’s definitive proxy statement on Schedule 14A, as filed with the Securities and Exchange Commission on April 27, 2018, were voted on at the Annual Meeting. Set forth below are the final voting results for each of the proposals submitted to a vote of the shareholders.

1.

The nominees for election as Class II directors of the Company’s Board of Directors, each for a three year term, were elected based upon the following vote:

Nominee

For

Withheld

Broker Non-Votes

1. Anton G. Gueth

64,693,855

5,425,167

73,907,422

2. Robert P. Roche, Jr.

67,520,362

2,598,660

73,907,422

2.

The proposal to approve, on a non-binding, advisory basis, the compensation of our named executive officers (“say-on-pay”), was approved based upon the following votes:

For

Against

Abstain

Broker Non-Votes

66,080,130

3,199,689

839,203

73,907,422

3.The proposal to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018 was approved based upon the following votes:

For

Against

Abstain

140,224,381

1,366,336

2,435,727


About ANTARES PHARMA, INC. (NASDAQ:ATRS)

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company makes a reusable, needle-free spring action injection device, ZOMA-Jet or Twin-Jector, which is marketed through its partners for use with human growth hormone (hGH). The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

An ad to help with our costs